Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Ponatinib: Phase II started

Ariad began an open-label, U.S. Phase II trial to evaluate 45 mg oral ponatinib once daily in about 45 patients after prior failure

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE